Quarta describes senolytics as a proposed strategy against senescent cells
In this Milan Longevity Summit 2026 session description, Dr. Marco Quarta presents senolytics as a closely watched longevity-biotechnology area: therapies aiming to selectively remove senescent cells, while noting the challenge of translating preclinical findings into safe, effective human therapies. [1]
Automatic summary · not editorially reviewed
The key findings
The description says senescent cells accumulate with age and can release signals linked to chronic inflammation, tissue dysfunction and age-related disease. [1]
Senolytic therapies are described as aiming to selectively eliminate dysfunctional cells, potentially restoring healthier tissue environments and improving function. [1]
Dr. Quarta is described as examining the challenge of translating promising preclinical discoveries into safe and effective human therapies. [1]
The source at a glance
- Study type / format
- Video description of a conference session
- Population / context
- Attendees of a Milan Longevity Summit 2026 session; no patients or study participants are described.
- Summary based on
- Creator description
- Original publication
- August 8, 2026
Quarta's session topic: senescent cells and senolytics
The description says senescent cells accumulate as we age and can release signals linked to chronic inflammation, tissue dysfunction and age-related disease. Senolytic therapies, it says, aim to selectively eliminate these dysfunctional cells, potentially restoring healthier tissue environments and improving function. The session sits within Targeting Ageing: Emerging Therapeutic Strategies at the Milan Longevity Summit 2026.
Supporting source [1]
Preclinical promise versus human translation in Quarta's talk
According to the description, Dr. Quarta examines where the field stands today, from the evolving understanding of cellular senescence to the challenge of translating promising preclinical discoveries into safe and effective human therapies. The presentation is described as covering both the potential and the scientific hurdles of this strategy. The description does not report specific study results, treated participants or measured outcomes.
Supporting source [1]
Speaker role and summit framing in the description
The description identifies Dr. Marco Quarta as Founder and Chief Scientific Officer of Rubedo Life Sciences, a biotechnology company developing therapies targeting pathological cells associated with ageing and chronic disease. It also describes the Milan Longevity Summit as bringing together leaders across science, medicine, policy, business, technology and society under a One Health perspective. These are stated roles and event framing, not evidence that any senolytic therapy is safe or effective in people.
Supporting source [1]
How to interpret this
This explainer is based only on the supplied video description. The video and transcript were not reviewed, and the description reports no study design, sample, follow-up or measured outcomes. Statements about senolytics are described as aims and potential, not demonstrated human benefits.
Based on the creator’s description; the full video and transcript were not analyzed.
Source & supporting passages
Milan Longevity Summit · youtube.com · August 8, 2026